- Home
- QLGN vs NDRA Comparison
QLGN vs NDRA Comparison
Compare QLGN & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- NDRA
- Stock Information
- Founded
- QLGN 1996
- NDRA 2007
- Country
- QLGN United States
- NDRA United States
- Employees
- QLGN N/A
- NDRA N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- QLGN Health Care
- NDRA Health Care
- Exchange
- QLGN Nasdaq
- NDRA Nasdaq
- Market Cap
- QLGN 4.8M
- NDRA 3.9M
- IPO Year
- QLGN N/A
- NDRA 2017
- Fundamental
- Price
- QLGN $5.02
- NDRA $6.23
- Analyst Decision
- QLGN
- NDRA Strong Buy
- Analyst Count
- QLGN 0
- NDRA 1
- Target Price
- QLGN N/A
- NDRA $38.00
- AVG Volume (30 Days)
- QLGN 4.8M
- NDRA 39.3K
- Earning Date
- QLGN 11-13-2025
- NDRA 11-14-2025
- Dividend Yield
- QLGN N/A
- NDRA N/A
- EPS Growth
- QLGN N/A
- NDRA N/A
- EPS
- QLGN N/A
- NDRA N/A
- Revenue
- QLGN N/A
- NDRA N/A
- Revenue This Year
- QLGN N/A
- NDRA N/A
- Revenue Next Year
- QLGN N/A
- NDRA N/A
- P/E Ratio
- QLGN N/A
- NDRA N/A
- Revenue Growth
- QLGN N/A
- NDRA N/A
- 52 Week Low
- QLGN $1.61
- NDRA $2.90
- 52 Week High
- QLGN $10.45
- NDRA $22.68
- Technical
- Relative Strength Index (RSI)
- QLGN 61.57
- NDRA 77.03
- Support Level
- QLGN $4.91
- NDRA $5.30
- Resistance Level
- QLGN $6.16
- NDRA $6.09
- Average True Range (ATR)
- QLGN 1.00
- NDRA 0.39
- MACD
- QLGN 0.06
- NDRA 0.15
- Stochastic Oscillator
- QLGN 43.01
- NDRA 86.86
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.